Mémoire de Diplôme dEtudes Supérieures dHépato-Gastro-Enterologie Nicolas Williet Inflamm Bowel Dis (In press) Inflamm Bowel Dis (In press) Le 15 Octobre.
Riesgo de tumores en la eii
La terapia con anti TNF alfa nella Rettocolite Ulcerosa - Gastrolearning®
enfermedad inflamatoria intestinal.pptx
Antibiotics and Risk of New Onset Inflammatory Bowel Disease: A Meta-Analysis Ryan Ungaro 1, Charles Bernstein 2, Richard Gearry 3, Anders Hviid 4, Kaija-Leena.
Other Major Side Effects to Immunomodulators and/or Biologics in Our IBD Patients Edward V. Loftus, Jr., M.D. Professor of Medicine Mayo Clinic Rochester,
What is the Deal About FMT? Herbert L. DuPont, MD Director, Center for Infectious Diseases, University of Texas School of Public Health President, Kelsey.
When Should We Stop Anti-TNF Therapy and How Do We Then Treat the Patient?
Thomas A. Ullman, M.D. Chief Medical Officer Mount Sinai Doctors Faculty Practice
David G. Binion , MD Bruce E. Sands, MD, MS
Other Major Side Effects to Immunomodulators and/or Biologics in Our IBD Patients
Antibiotics and Risk of New Onset Inflammatory Bowel Disease: A Meta-Analysis
